Clinics and practice
June 12, 2026
Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.
Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...
European Psychiatry
June 1, 2026
M. Pastre, F. Pereira, T. Gibert et al.
Introduction Treatment-resistant depression (TRD) remains a major clinical challenge, with limited efficacy of available therapies. Psilocybin, a serotonergic psychedelic, has shown promising antidepressant effects. As recent studies have shown altered default mode network activity following psilocybin administration, further neuroimaging research in clinical populations is needed to clarify...
European psychiatry : the journal of the Association of European Psychiatrists
August 26, 2025
Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al.
2 citations
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....
Medecine sciences : M/S
May 1, 2025
Aiste Lengvenyte, Emilie Olié, Marion Leboyer et al.
Suicidal thoughts and behaviors represent a transdiagnostic dimension independent of traditional psychiatric diagnoses. This specificity is supported by genetic studies, biomarkers, and preclinical research on endophenotypes associated with suicidal behaviors, such as impulsivity, anhedonia, and hopelessness. Clear mechanisms involving inflammation, the stress response, the serotonergic system,...
International Journal of Environmental Research and Public Health
March 27, 2025
Déborah Ducasse, Martin Leurent, Marie-Christine Picot et al.
1 citation
According to ontological addiction theory, the root cause of mental suffering is a dysfunctional conceptualisation of the self. Typically, an individual with such a flawed self-concept deems themselves to be intrinsically separate from their surroundings, with their beliefs, choices and behaviours structured in order to reinforce their sense of an independently existing self. The Ontological...
British medical journal
February 2, 2022
M. Abbar, C. Demattei, Wissam El-Hage et al.
172 citations
Abstract Objective To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group. Design Prospective, double blind, superiority, randomised placebo controlled trial. Setting Seven French teaching hospitals between 13 April 2015 and 12 March 2019. Eligibility criteria for participants Aged 18 or older with current...
Pharmaceuticals
November 24, 2021
Robertas Strumila, Bénédicte Nobile, Laura Korsakova et al.
35 citations
The available interventions for people who are at risk of suicide have limited efficacy. Recently, research on new mental health treatments has started to consider psychedelic compounds, particularly psilocybin, a molecule with a few thousand years of history of use in human societies. The possible effects of psilocybin on suicidal ideation and behaviors have not been specifically studied yet;...
Front Psychiatry
November 26, 2020
Bénédicte Nobile, Emilie Olié, Philippe Courtet
2 citations
Commentary: Psychedelic Psychiatry's Brave New World.